Divi's Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+12.8%+10.8%
EBITDA+15.9%+13.3%
Net Income+17.2%+12.1%
EPS (adj.)+17.2%+12.1%
Total Assets+18.3%+11.5%
Total Equity+12.0%+9.5%
Free Cash Flow+1.4%−52.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DIVISLAB₹9,558.50

Divi's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.53L Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+12.8+10.8
EBITDA+15.9+13.3
Net Income+17.2+12.1
EPS (adj.)+17.2+12.1
Total Assets+18.3+11.5
Total Equity+12.0+9.5
Free Cash Flow+1.4-52.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.